The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial.
 
Michael Masetti
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Immutep; Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Lilly; MacroGenics; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Immutep; Ipsen; Lilly; Medac; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Meyers-Squibb; Daiichi Sankyo; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
Research Funding - Merck/Pfizer (Inst)
 
Jorge Riera-Knorrenschild
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche; Sanofi
 
Eray Goekkurt
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; MSD; Pfizer
 
Gunnar Folprecht
Honoraria - Bristol-Myers Squibb; Falk Foundation; Merck KGaA; Merck Sharp & Dohme; Roche/Genentech; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exact Sciences; Incyte; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Roche/Genentech; SERVIER
Research Funding - Merck KGaA
 
Thomas Jens Ettrich
Consulting or Advisory Role - AstraZeneca; Bayer; BMS GmbH & Co. KG; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Eisai; Incyte; Ipsen; Lilly; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Baxalta/Shire
Travel, Accommodations, Expenses - Ipsen
 
Udo Lindig
No Relationships to Disclose
 
Kim Barbara Luley
Honoraria - Pierre Fabre
Consulting or Advisory Role - SERVIER
Travel, Accommodations, Expenses - Alexion Pharmaceuticals
 
Daniel Pink
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst)
Speakers' Bureau - PharmaMar (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); PharmaMar (Inst); Roche (Inst)
 
Tobias Nicolaas Dechow
No Relationships to Disclose
 
Disorn Sookthai
Stock and Other Ownership Interests - Bayer
 
Sabine Junge
No Relationships to Disclose
 
Claudia Pauligk
No Relationships to Disclose
 
Sylvie Lorenzen
No Relationships to Disclose